Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia

References

• Lowenberg B, Downing J R, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Burnett A K, Kell J, Rowntree C. Acute myeloid leukemia: therapeutic indications. Curr Opin Hematol 2000; 7: 333–338
   PubMed Web of Science ®Google Scholar
• Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet J G, et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999; 94: 3135–3140
   PubMed Web of Science ®Google Scholar
• Buggins A G, Lea N, Gaken J, Darling D, Farzaneh F, Mufti G J, et al. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood 1999; 94: 3479–3490
   PubMed Web of Science ®Google Scholar
• Hirano N, Takahashi T, Takahashi T, Ohtake S, Hirashima K, Emi N, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168–1176
   PubMed Web of Science ®Google Scholar
• Notter M, Willinger T, Erben U, Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 2001; 97: 3138–3145
   PubMed Web of Science ®Google Scholar
• Reid D C. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112: 874–887
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman R M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Hart D N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–3287
   PubMed Web of Science ®Google Scholar
• Harrison B D, Adams J A, Briggs M, Brereton M L, Yin J A. Stimulation of autologous proliferative and cytotoxic T-cell responses by ‘leukemic dendritic cells’ derived from blast cells in acute myeloid leukemia. Blood 2001; 97: 2764–2771
   PubMed Web of Science ®Google Scholar
• Choudhury B A, Liang J C, Thomas E K, Flores-Romo L, Xie Q S, Agusala K, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780–786
   PubMed Web of Science ®Google Scholar
• Koski G K, Schwartz G N, Weng D E, Gress R E, Engels F H, Tsokos M, et al. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood 1999; 94: 1359–1371
   PubMed Web of Science ®Google Scholar
• Waclavicek M, Berer A, Oehler L, Stock J, Schloegl E, Majdic O, et al. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br J Haematol 2001; 114: 466–473
   PubMed Web of Science ®Google Scholar
• Westers T M, Stam A M, Scheper R M, Regelink J M, Nieuwint A M, Schuurhuis G J, et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother 2003; 52: 523–524
   Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stock-schlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Lee J J, Chung I J, Park M R, Ryang D W, Park C S, Kim H J. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk Res 2001; 25: 1067–1073
   PubMed Web of Science ®Google Scholar
• Gabrilovich D I, Ishida T, Nadaf S, Ohm J E, Carbone D P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963–2970
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150–4166
   PubMed Web of Science ®Google Scholar
• Ohm J E, Shurin M R, Esche C, Lotze M T, Carbone D P, Gabrilovich D I. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999; 163: 3260–3268
   PubMed Web of Science ®Google Scholar
• Almand B, Resser J R, Lindman B, Nadaf S, Clark J I, Kwon E D, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755–1766
   PubMed Web of Science ®Google Scholar
• Lee J J, Takei M, Hori S, Inoue Y, Harada Y, Tanosaki R, et al. The role of PGE(2) in the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression?. Stem Cells 2002; 20: 448–459
   PubMed Web of Science ®Google Scholar
• Lee J J, Nam C E, Nam J H, Lee H C, Chung I J, Park M S, et al. Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res 2004; 28: 517–524
   PubMed Web of Science ®Google Scholar
• McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210: 149–166
   PubMed Web of Science ®Google Scholar
• Choudhury A, Gajewski J L, Liang J C, Popat U, Claxton D F, Fliche K O, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133–1142
   PubMed Web of Science ®Google Scholar
• Bae Y S, Yi H J, Lee H Y, Jo E J, Kim J I, Lee T G, et al. Differential activation of formyl peptide receptor-like 1 by peptide ligands. J Immunol 2003; 171: 6807–6813
   PubMed Web of Science ®Google Scholar
• Lee J J, Choi B H, Nam J H, Park M S, Song W H, Yang D H, et al. The generation of leukemic dendritic cells from acute myeloid leukemia cells is potentiated by the addition of CD40 l at the terminal maturation stage. J Clin Apher 2004; 19: 130–136
   PubMed Web of Science ®Google Scholar
• Marten A, Renoth S, Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001; 86: 1029–1037
   PubMed Web of Science ®Google Scholar
• Le Y, Gong W, Li B, Dunlop N M, Shen W, Su S B, et al. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999; 163: 6777–6784
   PubMed Web of Science ®Google Scholar
• Hussong J W, Rodgers G M, Shami P J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313
   PubMed Web of Science ®Google Scholar
• Lee J J, Kook H, Park M S, Nam J H, Choi B H, Song W H, et al. Immunotherapyusing autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 2004; 19: 66–70
   PubMed Web of Science ®Google Scholar
• Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. Immunology 2002; 107: 20–27
   PubMed Web of Science ®Google Scholar